New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
05:59 EDTAZN, HSHStocks with implied volatility below IV index mean; AZN HSH
Stocks with implied volatility below IV index mean; AstraZeneca (AZN) 21, Hillshire Brands (HSN) 26.
News For AZN;HSH From The Last 14 Days
Check below for free stories on AZN;HSH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2014
09:04 EDTHSHTyson Foods sees completing Hillshire merger later today
Subscribe for More Information
06:27 EDTAZNAstraZeneca volatility increases on price movement
Subscribe for More Information
August 27, 2014
16:53 EDTHSHTyson, Hillshire announce expiration of the HSR waiting period
Subscribe for More Information
14:39 EDTHSHTyson, Hillshire Brands reach agreement with Department of Justice
Subscribe for More Information
14:25 EDTHSHDOJ requires Tyson to divest sow purchasing business in merger settlement
Subscribe for More Information
14:19 EDTHSHHillshire rebounds, back to flat after report of merger deal with DOJ
Shares of Tyson Foods (TSN), which had dropped briefly, are also back to being nearly unchanged.
14:17 EDTHSHTyson Foods, Hillshire enter settlement with U.S. over merger, Bloomberg says
Subscribe for More Information
14:14 EDTHSHHillshire Brands drops 3% to $61.05
Subscribe for More Information
09:05 EDTAZNAstraZeneca gefitinib granted orphan designation by FDA
Subscribe for More Information
August 26, 2014
13:03 EDTHSHTyson Foods, Hillshire Brands announce extension of tender offer
Tyson Foods (TSN) and The Hillshire Brands Company (HSH) announced that Tyson has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares of common stock of Hillshire Brands for $63.00 per share in cash, without interest, subject to any withholding of taxes required by applicable law and upon the terms and subject to the conditions set forth in the Offer to Purchase dated July 16. Pursuant to the Agreement and Plan of Merger, dated July 1, by and among Tyson, HMB Holdings and Hillshire Brands, the Offer, which was previously scheduled to expire at 12:00 midnight, New York City time, at the end of Tuesday, August 26, has been extended until 12:00 midnight, New York City time, on Wednesday, August 27, unless it is extended further under the circumstances set forth in the Merger Agreement. All terms and conditions of the Offer shall remain unchanged during the extended period.
August 25, 2014
06:29 EDTAZNPfizer mulls possible AstraZeneca offer options, FT says
Subscribe for More Information
August 22, 2014
10:07 EDTAZNOptions with increasing implied volatility: ORPH EXAS AZN
Subscribe for More Information
05:19 EDTAZNStocks with implied volatility movement; JRJC AZN
Subscribe for More Information
August 21, 2014
09:54 EDTAZNPotential Pfizer, AstraZeneca deal seen around year-end, Reuters says
Investors and analysts see Pfizer (PFE) making another attempt to acquire AstraZeneca (AZN) around year-end, even though talks between the two can resume on August 26 per British takeover rules, Reuters reports. Reference Link
07:47 EDTAZNPfizer looking at new targets, including Actavis, Bloomberg reports
While it weighs another attempt to acquire AstraZeneca (AZN), Pfizer is considering other overseas alternatives, including Actavis (ACT), Bloomberg reports, citing people familiar with the matter. Pfizer prefers to reach a deal with AstraZeneca, and a move on another company is unlikely "anytime soon," Bloomberg adds, citing its sources. Shares of Actavis are rising 3%, or $6.65, to $230.01 in pre-market trading, while AstraZeneca is up 2% to $72.59. Reference Link
05:42 EDTAZNIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 19, 2014
18:19 EDTHSHTyson, Hillshire announce extension of tender offer for shares of Hillshire
Subscribe for More Information
07:01 EDTAZNDOJ closes investigation into PLATO Brilinta clinical trial, plans no action
AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with BRILINTA tablets. The government is not planning any further action. Pascal Soriot, CEO, said: “We welcome the Department of Justice’s decision not to pursue further action. We have always had absolute confidence in the integrity of the PLATO trial and we are proud of the important benefit BRILINTA offers to patients around the world suffering from acute coronary syndrome. As one of AstraZeneca’s growth platforms, we remain committed to delivering the full potential of this important medicine.” As part of our continued commitment to advancing the science behind cardiovascular medicine, AstraZeneca has initiated a clinical trial program for BRILINTA, its largest program involving more than 80,000 patients worldwide.
August 18, 2014
07:57 EDTAZNCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use